Total Payments
$4,488
2024 Payments
$436.04
Companies
43
Transactions
211
Medicare Patients
1,166
Medicare Billing
$176,030
Payment Breakdown by Category
Food & Beverage$3,913 (87.2%)
Education$574.42 (12.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,913 | 195 | 87.2% |
| Education | $574.42 | 16 | 12.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $824.86 | 41 | $0 (2024) |
| Lilly USA, LLC | $368.48 | 10 | $0 (2022) |
| Daiichi Sankyo Inc. | $329.62 | 13 | $0 (2024) |
| PFIZER INC. | $324.41 | 27 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $322.03 | 8 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $314.31 | 8 | $0 (2023) |
| Genentech USA, Inc. | $195.97 | 16 | $0 (2020) |
| Exelixis Inc. | $190.61 | 4 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $178.96 | 4 | $0 (2024) |
| Amgen Inc. | $163.31 | 12 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $436.04 | 25 | Daiichi Sankyo Inc. ($135.83) |
| 2023 | $356.16 | 19 | PFIZER INC. ($119.35) |
| 2022 | $183.48 | 8 | Lilly USA, LLC ($71.20) |
| 2021 | $283.26 | 6 | Astellas Pharma US Inc ($99.95) |
| 2020 | $227.21 | 8 | Daiichi Sankyo Inc. ($124.59) |
| 2019 | $726.50 | 39 | Lilly USA, LLC ($138.45) |
| 2018 | $1,511 | 67 | Novartis Pharmaceuticals Corporation ($301.11) |
| 2017 | $764.42 | 39 | Novartis Pharmaceuticals Corporation ($265.75) |
All Payment Transactions
211 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Oncology | ||||||
| 12/12/2024 | JAZZ PHARMACEUTICALS INC. | ZIIHERA (Drug) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 11/26/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $22.58 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | JAZZ PHARMACEUTICALS INC. | — | Food and Beverage | In-kind items and services | $22.50 | General |
| 11/13/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $25.88 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.92 | General |
| 10/10/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: HEMATOLOGY | ||||||
| 08/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Oncology | ||||||
| 06/05/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 05/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: ONCOLOGY | ||||||
| 04/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.08 | General |
| 03/20/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Oncology | ||||||
| 03/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $12.30 | General |
| Category: ONCOLOGY | ||||||
| 01/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $11.74 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 280 | 479 | $94,060 | $34,543 |
| 2022 | 4 | 284 | 488 | $97,162 | $40,506 |
| 2021 | 5 | 284 | 536 | $97,546 | $49,476 |
| 2020 | 4 | 318 | 647 | $117,509 | $51,504 |
Total Patients
1,166
Total Services
2,150
Medicare Billing
$176,030
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 116 | 254 | $53,086 | $19,266 | 36.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 120 | 165 | $23,430 | $8,450 | 36.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 41 | $11,521 | $4,715 | 40.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 19 | 19 | $6,023 | $2,112 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 130 | 277 | $57,893 | $24,536 | 42.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 110 | 150 | $21,300 | $8,263 | 38.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 38 | $10,678 | $5,024 | 47.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $7,291 | $2,684 | 36.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 91 | 201 | $42,009 | $18,206 | 43.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 15 | 84 | $13,440 | $13,459 | 100.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 142 | 210 | $29,820 | $12,788 | 42.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 15 | 20 | $5,620 | $2,633 | 46.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 21 | 21 | $6,657 | $2,390 | 35.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 106 | 231 | $48,279 | $16,473 | 34.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 21 | 101 | $16,160 | $16,042 | 99.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 163 | 255 | $36,210 | $12,375 | 34.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 28 | 60 | $16,860 | $6,614 | 39.2% |
About Dr. Jennifer Trottman, MD
Dr. Jennifer Trottman, MD is a Hematology & Oncology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457393696.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Trottman, MD has received a total of $4,488 in payments from pharmaceutical and medical device companies, with $436.04 received in 2024. These payments were reported across 211 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($3,913).
As a Medicare-enrolled provider, Trottman has provided services to 1,166 Medicare beneficiaries, totaling 2,150 services with total Medicare billing of $176,030. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tulsa, OK
- Active Since 06/12/2006
- Last Updated 05/30/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1457393696
Products in Payments
- Enhertu (Drug) $329.62
- OPDIVO (Biological) $314.31
- Cabometyx (Drug) $190.61
- TASIGNA (Drug) $178.34
- IBRANCE (Drug) $156.77
- LYNPARZA (Drug) $149.66
- KISQALI (Drug) $143.86
- RYDAPT (Drug) $137.07
- VERZENIO (Drug) $125.09
- TAGRISSO (Drug) $124.99
- AFINITOR (Drug) $119.42
- PROMACTA (Drug) $101.33
- TECENTRIQ (Biological) $90.02
- KEYTRUDA (Biological) $88.15
- IMBRUVICA (Drug) $86.01
- XALKORI (Drug) $75.30
- ZYTIGA (Drug) $74.99
- XTANDI (Drug) $74.33
- Imbruvica (Drug) $71.31
- Neulasta (Biological) $64.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tulsa
Dr. Edwin Mccreary, M.d, M.D
Hematology & Oncology — Payments: $477,532
Hematology & Oncology $477,532
Dr. Ali Moussa, M.d, M.D
Hematology & Oncology — Payments: $11,003
Hematology & Oncology $11,003
Supriya Koya, Md, MD
Hematology & Oncology — Payments: $6,558
Hematology & Oncology $6,558
Dr. Vicki Baker, M.d, M.D
Hematology & Oncology — Payments: $5,946
Hematology & Oncology $5,946
Dr. Mark Olsen, M.d, M.D
Hematology & Oncology — Payments: $4,652
Hematology & Oncology $4,652
Dr. Kevin Weibel, D.o, D.O
Hematology & Oncology — Payments: $4,174
Hematology & Oncology $4,174